Tetraphase plots Q4 launch for first an­tibi­ot­ic af­ter long-await­ed OK for er­ava­cy­cline

It took a few years more than ex­pect­ed, but Tetraphase fi­nal­ly has a prod­uct to sell.

Late Mon­day, the biotech an­nounced that the FDA has ap­proved their lead an­tibi­ot­ic, er­ava­cy­cline, for com­pli­cat­ed in­tra-ab­dom­i­nal in­fec­tions (cIAI). The com­pa­ny ex­pects to launch the in­tra­venous drug as Xer­a­va in the US by the end of the year.

Guy Mac­don­ald

The news comes four years af­ter Tetraphase first post­ed pos­i­tive Phase III da­ta for the drug in this in­di­ca­tion, back when the com­pa­ny thought the an­tibi­ot­ic could al­so treat com­pli­cat­ed uri­nary tract in­fec­tions (cU­TI). As er­ava­cy­cline flopped the late-stage study for cU­TI, reg­u­la­tors sent the com­pa­ny’s first NDA back de­mand­ing a sec­ond set of re­sults.

While the fol­low-up cU­TI study ul­ti­mate­ly proved to be equal­ly dis­ap­point­ing — ham­mer­ing the stock $TTPH and de­stroy­ing the pro­gram’s fu­ture — Tetraphase man­aged to build a new case around a promis­ing Phase III that, when com­bined with the first study, showed er­ava­cy­cline was non-in­fe­ri­or to the wide­ly used gener­ic an­tibi­otics er­tapen­em and meropen­em.

With a fi­nal de­ci­sion from Eu­ro­pean reg­u­la­tors com­ing up, com­mer­cial­iza­tion is now at the top of mind.

“We are thrilled to have re­ceived FDA ap­proval, and a pos­i­tive opin­ion from the Com­mit­tee for Med­i­c­i­nal Prod­ucts for Hu­man Use (CHMP) in Eu­rope all with­in the same quar­ter,” said CEO Guy Mac­don­ald in a state­ment. “We will now turn our ef­forts to­wards de­liv­er­ing Xer­a­va to pa­tients suf­fer­ing from cIAI in the Unit­ed States, an im­por­tant goal we ex­pect to be­gin ex­e­cut­ing on in the fourth quar­ter of this year.”

While the list price will be fi­nal­ized over the next few weeks, Mac­don­ald tells me it will fall with­in the range of $175 to $250 per day — dis­tin­guish­ing the drug from some re­cent­ly ap­proved an­tibi­otics, like Achao­gen’s Zem­dri, which are in­tend­ed to be used “ba­si­cal­ly where noth­ing else works.”

“We clear­ly want to pen­e­trate the first and sec­ond line mar­ket and get the drug used much ear­li­er,” he said. “Our la­bel sup­ports that, and the pric­ing strat­e­gy we pick as well.”

The fo­cus on com­pli­cat­ed pa­tients in hos­pi­tals, he adds, means their sales team can be con­cen­trat­ed in their ef­forts. So far, Tetraphase has built out a team of about 50, with 35 of those be­ing re­gion­al sales reps.

With Big Phar­ma bow­ing out of the an­tibi­otics field one by one — No­var­tis be­ing the lat­est to join the ex­o­dus — the tall charge of de­vel­op­ing new weapons for the bat­tle against grow­ing an­tibi­ot­ic re­sis­tance has large­ly fall­en on small­er biotechs. Tetraphase’s tech­nol­o­gy, li­censed from Har­vard, promis­es to im­prove up­on the tetra­cy­cline class of an­tibi­otics, mak­ing them pow­er­ful enough to over­come mul­tidrug re­sis­tance.

Philip Barie, a pro­fes­sor of surgery and pub­lic health at Weill Cor­nell Med­i­cine, put it this way:

Com­pli­cat­ed in­tra-ab­dom­i­nal in­fec­tions are the sec­ond-most preva­lent in­fec­tion site in in­ten­sive care units (ICUs), as well as the sec­ond lead­ing cause of in­fec­tion-re­lat­ed mor­tal­i­ty in ICUs. With the grow­ing cri­sis of an­tibi­ot­ic re­sis­tance, treat­ment op­tions for these polymi­cro­bial in­fec­tions are lim­it­ed fol­low­ing surgery or per­cu­ta­neous drainage, and the causative pathogens may be mul­ti-drug re­sis­tant. Cur­rent em­pir­ic treat­ments for cIAI have lim­i­ta­tions, and there is a need for new and nov­el treat­ments. Er­ava­cy­cline has a broad spec­trum of an­tibac­te­r­i­al ac­tiv­i­ty and a clin­i­cal pro­file that ad­dress­es this un­met med­ical need.

Tetraphase shares steadi­ly rose lead­ing up to the an­nounce­ment about the ap­proval, and has tak­en a 11% plunge since the news hit.

Brian Kaspar. AveXis via Twitter

AveX­is sci­en­tif­ic founder fires back at No­var­tis CEO Vas Narasimhan, 'cat­e­gor­i­cal­ly de­nies any wrong­do­ing'

Brian Kaspar’s head was among the first to roll at Novartis after company execs became aware of the fact that manipulated data had been included in its application for Zolgensma, now the world’s most expensive therapy.

But in his first public response, the scientific founder at AveXis — acquired by Novartis for $8.7 billion — is firing back. And he says that not only was he not involved in any wrongdoing, he’s ready to defend his name as needed.

I reached out to Brian Kaspar after Novartis put out word that he and his brother Allen had been axed in mid-May, two months after the company became aware of the allegations related to manipulated data. His response came back through his attorneys.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: Pay­back? An­a­lysts say Sarep­ta was blind­sided by an FDA re­jec­tion dri­ven by reg­u­la­to­ry re­venge

In one of the least anticipated moves of the year, the FDA has rejected Sarepta’s application for an accelerated approval of its Duchenne MD drug golodirsen after fretting over safety issues.

In a statement that arrived after the bell on Monday, Sarepta explained the CRL, saying:

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

FDA de­ci­sion on Ver­tex's CF triple will come just ahead of planned CEO shake­up

Vertex has clinched a priority review for the all-important cystic fibrosis triple that will blaze the trail for treating a large group of patients unhelped by its current drugs.

FDA regulators have set a PDUFA date of March 19, 2020, just a year after the Boston biotech posted positive Phase III results showing that people with two F508del mutations experienced statistically significant improvements in lung function after a 4-week regimen of VX-445, tezacaftor and ivacaftor. After reviewing 24-week data among patients with one F508del mutation and one minimal function mutation — and thoroughly comparing the VX-445 triple with another combo featuring VX-659 on scores like safety, drug-drug interactions, and photosensitivity — Vertex ultimately went with VX-445.

An MIT spin­out kills one of its ‘liv­ing ther­a­peu­tics’ af­ter flunk­ing an ear­ly-stage study — shares rout­ed

Just a few weeks after bagging $80 million in a deal to collaborate with Gingko Bioworks on its special blend of engineered bacteria used for “living therapeutics,” little Synlogic in Boston $SYBX is tossing one of its two clinical programs after watching an early-stage study go down in defeat.

Their Phase Ib/IIa study for SYNB1020 to counter the accumulation of ammonia in the body, a condition called hyperammonemia or urea cycle disorder, floundered at the interim readout, forcing the biotech to kill it and reserve its cash for pipeline therapies with greater potential.

Elan­co to buy Bay­er's an­i­mal health busi­ness for $7.6B, as deal­mak­ing gath­ers steam in the sec­tor

Last week, Elanco explicitly dodged answering questions about its rumored interest in Bayer’s animal health business in its post-earnings call. On Tuesday, the Eli Lilly spinoff disclosed it was purchasing the German drug maker’s veterinary unit in a cash-and-stock deal worth $7.6 billion. 

Elanco $ELAN has been busy on the deal-making front. In April, it laid out plans to swallow its partner, Kansas-based pet therapeutics company Aratana $PETX. A July report by Reuters suggested a potential Bayer deal was being explored, and Bloomberg last week said the deal was imminent, citing sources. 

As­traZeneca's di­a­betes drug Farx­i­ga helps pa­tients with heart dis­ease and with­out di­a­betes in land­mark tri­al

Months ago, data on J&J’s $JNJ Invokana indicated the diabetes drug conferred cardiovascular (CV) benefit in patients who do and do not have preexisting CV disease. On Tuesday, AstraZeneca’s $AZN rival treatment, Farxiga, was shown to cut the risk of CV death or the worsening of heart failure in patients with heart disease, in a landmark trial.

The treatments, in addition to Jardiance from Eli Lilly $LLY, belong to a class of diabetes drugs called sodium-glucose co-transporter 2 (SGLT2) inhibitors, which work by curbing the absorption of glucose via the kidneys so that surplus glucose is excreted through urination.

Levi Garraway. Broad Institute via Youtube

Roche raids Eli Lil­ly for its next chief med­ical of­fi­cer as San­dra Horn­ing plans to step down

We found out Monday morning where Levi Garraway was headed after he left Eli Lilly as head of oncology R&D a few days ago. Roche named Garraway as their new chief medical officer, replacing Sandra Horning, who they say is retiring from the company.

Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

Af­ter a posse of Wall Street an­a­lysts pre­dict a like­ly new win for Sarep­ta, we're down to the wire on a crit­i­cal FDA de­ci­sion

As Bloomberg notes, most of the Wall Street analysts that cover Sarepta $SRPT are an upbeat bunch, ready to cheer on the team when it comes to their Duchenne MD drugs, or offer explanations when an odd setback occurs — as happened recently with a safety signal that was ‘erroneously’ reported last week.

Ritu Baral Cowen
Endpoints News

Basic subscription required

Unlock this story instantly and join 57,700+ biopharma pros reading Endpoints daily — and it's free.

UP­DAT­ED: No­var­tis spin­off Nabri­va fi­nal­ly scores its first an­tibi­ot­ic ap­proval

In May, Nabriva Therapeutics suffered a setback after the FDA rejected its antibiotic for complicated urinary tract infections — the Novartis spinoff has now had some better luck with the US agency, which on Monday approved its other drug for community-acquired bacterial pneumonia.

The drug, lefamulin, has been developed as an intravenous and oral formulation and been tested in two late-stage clinical trials. The semi-synthetic compound, whose dosing can be switched between the two formulations, is engineered to inhibit the synthesis of bacterial protein by binding to a part of the bacterial ribosome.